Aliskiren/amlodipine/hydrochlorothiazide, sold under the brand name Amturnide, is a fixed-dose combination medication that is used to treat high blood pressure.[1][2] It contains aliskiren, a renin inhibitor; amlodipine, as the besylate, a calcium channel blocker; and hydrochlorothiazide, a thiazide diuretic.[1] It is taken by mouth.[1]
It was approved for medical use in the United States in December 2010.[1][3][4] Amturnide was withdrawn by Novartis from the US market in 2017.[5]
External links
References
- Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets, for oral use Initial U.S. Approval: 2010 DailyMed, 10 November 2016, retrieved 6 February 2022^
- Hypertension management: rationale for triple therapy based on mechanisms of action Cardiovascular Therapeutics, October 2013^
- Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets, for oral use Initial U.S. Approval: 2010 DailyMed, retrieved 5 July 2024^
- Drug Approval Package: Amturnide(amlodipine/aliskiren/hydrochlorothiazide) NDA #200045 U.S. Food and Drug Administration (FDA), 15 August 2011, retrieved 27 August 2020^
- Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications Federal Register, 21 June 2017, retrieved 6 February 2022^